# US 2025/0145666 A1 · Interleukin-13 binding cyclic oligopeptides and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145666 A1
- Document ID: US20250145666A1
- Status: Published application
- Kind: A1
- Application number: 18/952,863
- Filed: 2024-11-19
- Published: 2025-05-08
- Earliest claimed: 2022-06-13
- Assignees: B.A.I. Laboratories, LLC
- Applicants: B.A.I. Laboratories, LLC
- Inventors: Xuefei Bai; Sheng Lin; Le Li
- Web page: https://patentgrep.com/patent/US20250145666A1

## CPC

- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61P 17/00: Drugs for dermatological disorders
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to cyclic oligopeptides that bind to interleukin-13 (IL-13) which are useful therapeutically in methods of treating or preventing IL-13-associated skin disorders or conditions. The present disclosure also provides methods to treat or prevent IL-13-associated skin disorders or conditions with the IL-13-binding cyclic oligopeptides. The present disclosure further provides methods to produce the IL-13-binding cyclic oligopeptides.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A method of treating or preventing an IL-13-associated skin disorder or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a cyclic oligopeptide or a pharmaceutical composition comprising the cyclic oligopeptide and a pharmaceutically acceptable carrier, wherein the cyclic oligopeptide is selected from the group consisting of any one of Compounds 1-11
or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 22 (depends on 21)

The method of claim 21, wherein the IL-13-associated skin disorder or condition is selected from the group consisting of: allergic contact dermatitis, urticaria, eczema, chronic hand eczema, bullous disease, alopecia areata, prurigo and molluscum contagiosum.

### Claim 23 (depends on 22)

The method of claim 22, wherein the IL-13-associated skin disorder or condition is allergic contact dermatitis.

### Claim 24 (depends on 22)

The method of claim 22, wherein the IL-13-associated skin disorder or condition is urticaria.

### Claim 25 (depends on 22)

The method of claim 22, wherein the IL-13-associated skin disorder or condition is eczema.

### Claim 26 (depends on 22)

The method of claim 22, wherein the IL-13-associated skin disorder or condition is a bullous disease.

### Claim 27 (depends on 26)

The method of claim 26, wherein the bullous disease is bullous pemphigoid.

### Claim 28 (depends on 22)

The method of claim 22, wherein the IL-13-associated skin disorder or condition is alopecia areata.

### Claim 29 (depends on 22)

The method of claim 22, wherein the IL-13-associated skin disorder or condition is a prurigo.

### Claim 30 (depends on 22)

The method of claim 22, wherein the IL-13-associated skin disorder or condition is a molluscum contagiosum.

### Claim 31 (depends on 21)

The method of claim 21, wherein the cyclic oligopeptide is selected from the group consisting of any one of Compounds 1-11

### Claim 32 (depends on 21)

The method of claim 21, wherein the cyclic oligopeptide is a pharmaceutically acceptable salt of a compound selected from the group consisting of any one of Compounds 1-11

### Claim 33 (depends on 21)

The method according to claim 21, wherein the cyclic oligopeptide or pharmaceutical composition is administered topically, transdermally, or subcutaneously.

### Claim 34 (depends on 31)

The method according to claim 31, wherein the cyclic oligopeptide or pharmaceutical composition is administered topically, transdermally, subcutaneously.

### Claim 35 (depends on 32)

The method according to claim 32, wherein the cyclic oligopeptide or pharmaceutical composition is administered topically, transdermally, subcutaneously.

### Claim 36

A method of reducing the biological activities of IL-13 and/or an IL-13 receptor in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a cyclic oligopeptide or a pharmaceutical composition comprising the cyclic oligopeptide and a pharmaceutically acceptable carrier, wherein the cyclic oligopeptide is selected from the group consisting of any one of Compounds 1-11
or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 37 (depends on 36)

The method of claim 36, wherein the cyclic oligopeptide is selected from the group consisting of any one of Compounds 1-11

### Claim 38 (depends on 36)

The method of claim 36, wherein the cyclic oligopeptide is a pharmaceutically acceptable salt of a compound selected from the group consisting of any one of Compounds 1-11

### Claim 39 (depends on 36)

The method according to claim 36, wherein the cyclic oligopeptide or pharmaceutical composition is administered topically, transdermally, subcutaneously, intravenously, or orally.
